Home » Topics » Disease categories and therapies » Endocrine/metabolic

Endocrine/metabolic
RSS

Muse approved in U.K.

Dec. 2, 1997

Further labeling changes for Rezulin/Noscal; Romozin availability suspended in U.K.

Dec. 2, 1997

AHP describes new compounds with tissue-selective estrogenic and antiestrogenic effects

Dec. 1, 1997

Sankyo discloses agents for diabetes and related complications

Nov. 28, 1997

Lilly prepares new benzothiophenes

Nov. 28, 1997

New approvals for Menorest

Nov. 28, 1997

Negative phase II results for long-term risedronate in osteoporosis

Nov. 28, 1997

Launch of Ligand/Lilly metabolic disease alliance

Nov. 27, 1997

Agents activating beta3-adrenoceptors from Pfizer

Nov. 27, 1997

Beaufour-Ipsen moves TH-9506 to phase I

Nov. 27, 1997

Popular Stories

Today's news in brief
BioWorld
CROI 2026: Neurodegeneration, the challenge of aging with HIV
BioWorld
Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...
CROI 2026 highlights depression and cognitive vulnerability in HIV
BioWorld
The effects of aging pose an additional challenge for people with HIV due to the neurological and psychological consequences that persist despite antiretroviral...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
University of Southern California reports new MAPT aggregation inhibitors
BioWorld Science
The University of Southern California has identified (2-oxo-2H-chromen-3-yl) scaffold-based carboxamide analogues acting as potent microtubule-associated protein...